Amgen/Takeda VEGF Inhibitor Motesanib Faces Setback In NSCLC

Enrollment in a Phase III trial in NSCLC patients is suspended after early mortality rates were seen in the treatment arm.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet